These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21935911)

  • 21. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
    Lee JM; McMahon PM; Kong CY; Kopans DB; Ryan PD; Ozanne EM; Halpern EF; Gazelle GS
    Radiology; 2010 Mar; 254(3):793-800. PubMed ID: 20177093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Online tool to guide decisions for BRCA1/2 mutation carriers.
    Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
    J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
    Grann VR; Patel PR; Jacobson JS; Warner E; Heitjan DF; Ashby-Thompson M; Hershman DL; Neugut AI
    Breast Cancer Res Treat; 2011 Feb; 125(3):837-47. PubMed ID: 20644999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
    Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
    J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
    Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
    Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
    Shah P; Rosen M; Stopfer J; Siegfried J; Kaltman R; Mason B; Armstrong K; Nathanson KL; Schnall M; Domchek SM
    Breast Cancer Res Treat; 2009 Dec; 118(3):539-46. PubMed ID: 19609668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
    Obdeijn IM; Heijnsdijk EA; Hunink MG; Tilanus-Linthorst MM; de Koning HJ
    Eur J Cancer; 2016 Aug; 63():135-42. PubMed ID: 27318001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
    Lee JM; Kopans DB; McMahon PM; Halpern EF; Ryan PD; Weinstein MC; Gazelle GS
    Radiology; 2008 Mar; 246(3):763-71. PubMed ID: 18309013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
    Passaperuma K; Warner E; Causer PA; Hill KA; Messner S; Wong JW; Jong RA; Wright FC; Yaffe MJ; Ramsay EA; Balasingham S; Verity L; Eisen A; Curpen B; Shumak R; Plewes DB; Narod SA
    Br J Cancer; 2012 Jun; 107(1):24-30. PubMed ID: 22588560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.
    Warner E; Hill K; Causer P; Plewes D; Jong R; Yaffe M; Foulkes WD; Ghadirian P; Lynch H; Couch F; Wong J; Wright F; Sun P; Narod SA
    J Clin Oncol; 2011 May; 29(13):1664-9. PubMed ID: 21444874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
    Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
    Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
    Kurian AW; Sigal BM; Plevritis SK
    J Clin Oncol; 2010 Jan; 28(2):222-31. PubMed ID: 19996031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.